UCB SA (OTCMKTS:UCBJY - Get Free Report) shares hit a new 52-week high on Tuesday . The stock traded as high as $141.80 and last traded at $141.79, with a volume of 86380 shares trading hands. The stock had previously closed at $134.02.
Analyst Upgrades and Downgrades
UCBJY has been the subject of several analyst reports. The Goldman Sachs Group upgraded UCB to a "strong-buy" rating in a report on Wednesday, July 16th. Zacks Research upgraded UCB from a "hold" rating to a "strong-buy" rating in a report on Friday, August 29th. Two analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Strong Buy".
Read Our Latest Stock Report on UCB
UCB Price Performance
The company has a current ratio of 1.36, a quick ratio of 0.99 and a debt-to-equity ratio of 0.30. The business's 50-day moving average is $114.59 and its two-hundred day moving average is $99.07.
About UCB
(
Get Free Report)
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UCB, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.
While UCB currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
